logo

For the Inventor, By the Inventor

Norwich, NY, United States of America

Robert J Alaimo

USPTO Granted Patents = 17

Average Co-Inventor Count = 1.5

ph-index = 4

Forward Citations = 52(Granted Patents)


Company Filing History:

goldMedal13 out of 190 
 
Morton-Norwich Products, Inc.
 patents
silverMedal4 out of 47 
 
Norwich Eaton Pharmaceuticals, Inc.
 patents

Years Active: 1976-1987

Loading Chart...
17 patents (USPTO):Explore Patents
1. 4716168 - Imidazo(4,5-f)quinolines useful as immunomodulating agents (1987-12-29),
2. 4540693 - Thiocyanatoquinoxaline compounds with immunomodulating activity (1985-09-10),
3. 4393208 - 5-Methyl-2-trifluoromethylindolo[2,3-b]quinoxaline (1983-07-12),
4. 4381394 - 6,7-Dichloro-2-[(methy (1983-04-26),
5. 4339386 - 5-[(3,4-Dimethoxyphenyl)or(4-chlorophenyl)]-2-furancarboxa (1982-07-13),
6. 4336199 - 5-(2,4-Dichlorophenyl)-3-furancarboxaldehyde- (1982-06-22),
7. 4332735 - Antifungal compound (1982-06-01),
8. 4225526 - 8-[(4-Aminophenyl)sulfonyl]amino-2-naphthalenyl phosphorodiamidate (1980-09-30),
9. 4222948 - [[(4-Aminophenyl)sulfonyl]amino]phenyl phosphorodiamidates (1980-09-16),
10. 4221730 - 3-[[(4-Aminophenyl)sulfonyl]amino]-N-[diaminophosphinyl]-benzamide (1980-09-09),
11. 4028374 - Antibacterial thiocyanatobenzothiazoles (1977-06-07),
12. 4020075 - 2-Bromo-1-hydroxyquinolizinium bromide substituted anilinium salts (1977-04-26),
13. 4012409 - N-(6-Ethyl-4-thiocyanato-2-benzothiazolyl)-5-nitrofuramide (1977-03-15),
14. 3997547 - Phenylimino-2H-quinolizines (1976-12-14),
15. 3997538 - 2-(3,4-Dichlorophenyl)-4-(substituted amino)-quinazolines (1976-12-14),

Title: The Innovative Contributions of Robert J. Alaimo

Introduction

Robert J. Alaimo, an accomplished inventor based in Norwich, NY, has made significant strides in the field of immunology through his innovative research. With a portfolio of 17 patents to his name, Alaimo has dedicated his career to developing compounds that enhance immune response systems in mammals. His work exemplifies the nexus of scientific inquiry and practical application, making substantial impacts in the health sector.

Latest Patents

Among Alaimo's noteworthy contributions are two groundbreaking patents. The first, titled "Imidazo(4,5-f)quinolines useful as immunomodulating agents," focuses on compounds within the imidazo[4,5-f]quinoline class. This invention details methods for enhancing the immune response in mammals by systemically administering non-toxic amounts of these compounds to individuals with depressed immune functions. The second patent, named "Thiocyanatoquinoxaline compounds with immunomodulating activity," introduces new thiocyanatoquinoxaline compounds, characterized by a specific general formula. These compounds are designed to serve as effective immunomodulating agents, showcasing Alaimo's commitment to advancing medical treatments.

Career Highlights

Robert J. Alaimo has contributed significantly to the pharmaceutical industry throughout his career. He has held positions with notable companies such as Morton-Norwich Products, Inc. and Norwich Eaton Pharmaceuticals, Inc. These roles provided him with valuable opportunities to apply his innovative ideas and develop new products aimed at improving health outcomes.

Collaborations

Collaboration has been a key aspect of Alaimo's success. He has worked alongside esteemed colleagues, including Ozra E. Millner, Jr. and Joseph E. Gray. These partnerships have enabled him to leverage diverse expertise, fostering an environment where groundbreaking ideas can flourish.

Conclusion

Robert J. Alaimo's contributions to immunology and pharmaceutical innovations stand as a testament to his dedication and ingenuity. With 17 patents and a commitment to enhancing the immune response, his work continues to influence the development of new therapies. As the landscape of medicine evolves, Alaimo's innovative spirit is sure to inspire future inventors and researchers in their endeavors.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…